The federal government has patented CBD. Here is what they say in their patent abstract:
“treatment of neurodegenerative diseases, such as… Dementia”.
CBD (Cannabinoids) has been found to have antioxidant properties, unrelated to NMDA receptor antagonism. This new found property makes cannabinoids useful in the treatment and prophylaxis of wide variety of oxidation associated diseases, such as ischemic, age-related, inflammatory and autoimmune diseases. The cannabinoids are found to have particular application as neuroprotectants, for example in limiting neurological damage following ischemic insults, such as stroke and trauma, or in the treatment of neurodegenerative diseases, such as Alzheimer’s disease, Parkinson’s disease and Dementia. Non-psychoactive cannabinoids, such as cannabidiol, are particularly advantageous to use because they avoid toxicity that is encountered with psychoactive cannabinoids at high doses useful in the method of the present invention. According to research published in Neurotherapeutics, CBD may be an outstanding option in reducing General Anxiety, Obsessive Compulsive Disorder, Post Traumatic Stress Disorder, Social Anxiety Disorder and Panic Disorders that may be associated with Dementia.